Sava Technologies, a London-based health technology company behind a next-generation glucose microsensor, has raised $36 million (£27m). The Series B funding was secured alongside an agreement appointing Ascensia, a subsidiary of PHC Holdings Corporation, as its commercialisation and distribution partner, initially in Europe. The round brings Sava’s total funding to $68m. The round was led … Continue reading Sava secures £27m to transform health monitoring